34175 Ardenwood Boulevard
190 articles with Ardelyx Inc.
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus.
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology (ACG) 2018 Annual Meeting.
Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City.
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Tenapanor is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut.
Operating Runway Extended to Mid-2020
Ardelyx, Inc. announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other business updates.
Ardelyx Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock.
Knight Therapeutics announced a license agreement with Ardelyx Inc. that provides Knight with exclusive rights to commercialize tenapanor in Canada.
Ardelyx Inc. announced a license agreement with Knight Therapeutics Inc. that provides Knight with exclusive rights to commercialize tenapanor in Canada.
Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Ardelyx, Inc. reported pipeline highlights and financial results for the fourth quarter and full-year ended December 31, 2017.
Ardelyx today announced that Jeremy Caldwell, Ph.D., CSO, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San Diego.
Ardelyx today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with IBS-C.
The agreement also provides Fosun Pharma the rights to commercialize tenapanor for other indications for which it is approved in the U.S.
Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million.
Ardelyx updated two of its programs today.
Ardelyx, today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017.
10/25/2017The drug developed by Nogra always seemed like a longshot, but Celgene management talked it up over the years as it advanced.
Biotech stocks are generally viewed as highly volatile. Of course, along with volatility comes the possibility for huge upside rewards.
Ardelyx today reported that data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation (IBS-C) through the inhibition of TRPV-1 dependent signaling